Just In
- 3 hrs ago New Book ‘Kathmandu Chronicle: Reclaiming India-Nepal Relations’ To Shed Light On Geopolitical Uncertainties
- 7 hrs ago Russian Influencer Starves His Newborn To Death With Sunlight Diet, Know Dos And Don’ts Of This Diet
- 9 hrs ago Mahavir Jayanti 2024: Date, Time, History, Celebrations And Teachings Of Lord Mahavir In Jainism
- 10 hrs ago Parineeti Chopra Saree Looks: Check Amar Singh Chamkila Actor's Regal Fashion Statements
Don't Miss
- Sports Highest Powerplay Score In IPL: Sunrisers Hyderabad Pummell Delhi Capitals to Post Highest T20 Score In First 6 Overs
- Finance 18K, 22K, 24K Gold Prices India Get Cheaper: Yellow Metal Prices Fall On Weekend
- Education UP Board Result 2024: 82% of Jail Inmates Passed the Class 12 and 97% of the Class 10
- News Bengaluru Water Crisis: PM Modi Slams Karnataka Congress, Says Mismanagement Turned Tech City To Tanker City
- Movies Queen Of Tears Episode 14 OTT Release Date, Time, Platform: When & Where To Watch? What To Expect? DEETS Out
- Automobiles Tata Altroz Records a 55% Sales Growth in March 2024
- Technology Best Noise-Cancelling Earbuds Under Rs 5,000: CMF Buds Pro, Redmi Buds 5, Realme Buds Air 5, and More
- Travel Journey From Delhi To Ooty: Top Transport Options And Attractions
Serum Institute CEO Hails WHO's Approval Of Covovax For Emergency Use
Serum Institute of India (SII) CEO Adar Poonawalla on Friday hailed WHO's approval for emergency use of the Covovax vaccine "as yet another milestone" in the fight against Covid-19.
The World Health Organization (WHO) on Friday listed the Covovax as the ninth Covid-19 vaccine for emergency use with an aim to increase access to vaccination in lower-income countries.
It is produced by the Serum Institute of India under the licence of Novavax.
Reacting to the development, Poonawalla tweeted, "This is yet another milestone in our fight against Covid-19, Covovax is now WHO approved for emergency use, showing excellent safety and efficacy. Thank you all for a great collaboration..."
He tagged Novavax, WHO, Gavi, the Vaccine Alliance, its CEO Seth Berkley and the Gates Foundation. Currently, Covishield and other Covid-19 vaccines are approved for people above the age of 18.
According to WHO, Covovax was assessed under its emergency use listing (EUL) procedure based on the review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and manufacturing site inspections carried out by the Drugs Controller General of India.
"The Technical Advisory Group for Emergency Use Listing (TAG-EUL), convened by WHO and made up of experts from around the world, has determined that the vaccine meets WHO standards for protection against Covid-19, that the benefit of the vaccine far outweighs any risks, and that the vaccine can be used globally," it said.
- wellnessCervical Cancer Vaccine: All You Need To Know About India's Self-Developed HPV Vaccine
- wellnessDCGI Approves India's First qHPV Vaccine Against Cervical Cancer
- kidsSerum Institute Seeks Covovax's Inclusion In Covid Vaccination Drive For 12 Years And Over
- wellnessDCGI Grants Emergency Use Authorisation To Covovax For 12-17 Years Age Group; Younger Age Groups To Follow
- healthReduce Gap Between 2nd Dose And Precaution Dose Of Covishield, Urges Serum Institute To Health Ministry
- healthSerum Institute Urges Govt To Fast-Track Movement Of Increasing Covishield Stock
- healthGovernment Allows Serum Institute To Export 50 Lakh Covishield Doses Under Covax To 4 Nations
- wellnessGovt Panel Recommends Emergency Approval For SII's Covovax For 7-11 Year Olds
- kidsDCGI Panel To Review On Friday SII Applications For Covovax’s Use Among Kids Aged 2-7 Yrs, 7-11 Yrs
- basicsNovavax's Covid-19 Vaccine Covovax Gets Emergency Use Authorisation For 12-17 Age Group In India
- wellnessGovt Panel Recommends Permission For Phase-3 Trial Of Covovax As Booster Dose In Adults
- wellnessSII Seeks Permission For Phase-3 Study Of Covid Vaccine Covovax As Booster Dose In Adults